Cocrystal Pharma, Inc. (COCP) is a publicly traded company in the Unknown sector. Across all available filings, 14 corporate insiders have executed 64 transactions totaling $19.6M, demonstrating a bullish sentiment with $14.3M in net insider flow. The most recent transaction on Jan 9, 2026 involved a transaction of 24,615 shares valued at $0.
No significant insider buying has been recorded for COCP in the recent period.
No significant insider selling has been recorded for COCP in the recent period.
Based on recent SEC filings, insider sentiment for COCP is bullish with an Insider Alignment Score of 86/100 and a net flow of $14.3M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Cocrystal Pharma, Inc. (COCP) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 14 insiders are actively trading COCP stock, having executed 64 transactions in the past 90 days. The most active insider is Raymond F. Schinazi (Executive), who has made 13 transactions totaling $10.8M.
Get notified when executives and directors at COCP file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 9, 2026 | D. Kornberg Roger | Executive | Award | 24,615 | $N/A | $0 | |
| Jan 9, 2026 | D. Rubin Steven | Executive | Award | 16,410 | $N/A | $0 | |
| Jan 9, 2026 | J. Japour Anthony | Executive | Award | 16,410 | $N/A | $0 | |
| Jan 9, 2026 | Md Et Al Frost Phillip | Executive | Award | 24,615 | $N/A | $0 | |
| Jan 9, 2026 | Joseph Martin James | Co-CEO and CFO | Award | 49,229 | $N/A | $0 | C-Suite |
| Jan 9, 2026 | Hassan Fred | Executive | Award | 16,410 | $N/A | $0 | |
| Jan 9, 2026 | Lee Sam | President and Co-CEO | Award | 49,229 | $N/A | $0 | C-Suite |
| Jan 9, 2026 | C. Pfenniger Richard Jr | Executive | Award | 16,410 | $N/A | $0 | |
| Dec 30, 2025 | Md Et Al Frost Phillip | Executive | Purchase | 20,000 | $0.97 | $19.4K | |
| Dec 26, 2025 | Md Et Al Frost Phillip | Executive | Purchase | 40,000 | $0.97 | $38.8K | |
| Dec 24, 2025 | Md Et Al Frost Phillip | Executive | Purchase | 25,000 | $0.97 | $24.3K | |
| Nov 26, 2025 | Md Et Al Frost Phillip | Executive | Purchase | 1,500 | $1.00 | $1.5K | |
| Nov 26, 2025 | Md Et Al Frost Phillip | Executive | Purchase | 2,500 | $0.99 | $2.5K | |
| Nov 25, 2025 | Md Et Al Frost Phillip | Executive | Purchase | 20,000 | $0.94 | $18.8K | |
| Oct 28, 2025 | Joseph Martin James | Executive | Award | 3,598 | $1.39 | $5.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 38 | $16.9M | 73.0% |
Award(A) | 16 | $3.0M | 13.0% |
Sale(S) | 2 | $2.7M | 11.5% |
Exercise(M) | 8 | $585.3K | 2.5% |
Insiders at Cocrystal Pharma, Inc. are accumulating shares at an accelerated pace. With 14 insiders making 64 transactions totaling $16.9M in purchases versus $2.7M in sales, the net buying activity of $14.3M signals strong executive confidence. Raymond F. Schinazi (Executive) leads the buying activity with $10.8M in transactions across all time.